Elon H C van Dijk1, Danial Mohabati1, Simona Veselinovic1, Wing H Chung1, Greet Dijkman1, Camiel J F Boon2,3,4. 1. Department of Ophthalmology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. 2. Department of Ophthalmology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. c.j.f.boon@lumc.nl. 3. Department of Ophthalmology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands. c.j.f.boon@lumc.nl. 4. Department of Ophthalmology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands. c.j.f.boon@lumc.nl.
Abstract
PURPOSE: To describe the clinical characteristics and outcome of polypoidal choroidal vasculopathy (PCV), also known as aneurysmal type 1 (sub-retinal pigment epithelium (RPE)) neovascularization, in Caucasian patients. METHODS: Single-centre study in 66 Caucasian patients with a diagnosis of PCV based on optical coherence tomography scan and indocyanine green angiography. Clinical characteristics and multimodal imaging were collected and assessed by an experienced retina specialist. RESULTS: This study involved 74 eyes of 66 patients with PCV, with a mean age at onset of 73 years and a female preponderance of 66%. The mean number of polypoidal lesions per eye was 1 (range: 1-5 lesions), out of which 75% was located in the macula and 19% in the peripapillary region. Of the 74 eyes, 37 eyes (50%) had PCV associated with a drusenoidal neovascular age-related macular degeneration (AMD) phenotype (PCV-AMD) and 18 eyes (24%) had PCV associated with non-polypoidal type 1 choroidal neovascularization/branching vascular network (PCV-BVN) without signs of drusenoidal AMD, while 19 eyes (26%) had idiopathic, isolated PCV (iPCV). The mean subfoveal choroidal thickness measured in 22 patients was 245 μm (range: 71-420 μm). In 51% of patients, the initially performed therapy showed good anatomical recovery (resolution of intra- and subretinal fluid). CONCLUSIONS: A spectrum of PCV (aneurysmal type 1/sub-RPE neovascularization) can be seen in Caucasian patients. PCV associated with a drusenoidal neovascular AMD phenotype in Caucasians is phenotypically and presumably pathophysiologically more associated with neovascular AMD (PCV-AMD: type A PCV). However, this may not be the case for patients with PCV with non-polypoidal type 1 choroidal neovascularization or BVN and no signs of drusenoidal AMD (PCV-BVN: type B PCV), and for patients with idiopathic PCV without associated drusen or BVN (iPCV; type C PCV). Most patients have a thin choroid, even when drusen are absent. For the entire patient group, a moderate anatomical recovery was observed after treatment.
PURPOSE: To describe the clinical characteristics and outcome of polypoidal choroidal vasculopathy (PCV), also known as aneurysmal type 1 (sub-retinal pigment epithelium (RPE)) neovascularization, in Caucasian patients. METHODS: Single-centre study in 66 Caucasian patients with a diagnosis of PCV based on optical coherence tomography scan and indocyanine green angiography. Clinical characteristics and multimodal imaging were collected and assessed by an experienced retina specialist. RESULTS: This study involved 74 eyes of 66 patients with PCV, with a mean age at onset of 73 years and a female preponderance of 66%. The mean number of polypoidal lesions per eye was 1 (range: 1-5 lesions), out of which 75% was located in the macula and 19% in the peripapillary region. Of the 74 eyes, 37 eyes (50%) had PCV associated with a drusenoidal neovascular age-related macular degeneration (AMD) phenotype (PCV-AMD) and 18 eyes (24%) had PCV associated with non-polypoidal type 1 choroidal neovascularization/branching vascular network (PCV-BVN) without signs of drusenoidal AMD, while 19 eyes (26%) had idiopathic, isolated PCV (iPCV). The mean subfoveal choroidal thickness measured in 22 patients was 245 μm (range: 71-420 μm). In 51% of patients, the initially performed therapy showed good anatomical recovery (resolution of intra- and subretinal fluid). CONCLUSIONS: A spectrum of PCV (aneurysmal type 1/sub-RPE neovascularization) can be seen in Caucasian patients. PCV associated with a drusenoidal neovascular AMD phenotype in Caucasians is phenotypically and presumably pathophysiologically more associated with neovascular AMD (PCV-AMD: type A PCV). However, this may not be the case for patients with PCV with non-polypoidal type 1 choroidal neovascularization or BVN and no signs of drusenoidal AMD (PCV-BVN: type B PCV), and for patients with idiopathic PCV without associated drusen or BVN (iPCV; type C PCV). Most patients have a thin choroid, even when drusen are absent. For the entire patient group, a moderate anatomical recovery was observed after treatment.
Authors: Gabriel Coscas; Marco Lupidi; Florence Coscas; Fayçal Benjelloun; Jennifer Zerbib; Ali Dirani; Oudy Semoun; Eric H Souied Journal: Invest Ophthalmol Vis Sci Date: 2015-05 Impact factor: 4.799
Authors: Chui Ming Gemmy Cheung; Timothy Y Y Lai; Paisan Ruamviboonsuk; Shih-Jen Chen; Youxin Chen; K Bailey Freund; Fomi Gomi; Adrian H Koh; Won-Ki Lee; Tien Yin Wong Journal: Ophthalmology Date: 2018-01-10 Impact factor: 12.079
Authors: Wing H Chung; Elon H C van Dijk; Danial Mohabati; Greet Dijkman; Suzanne Yzer; Eiko K de Jong; Sascha Fauser; Reinier O Schlingemann; Carel B Hoyng; Camiel J F Boon Journal: Clin Ophthalmol Date: 2016-12-21
Authors: Kunal K Dansingani; Orly Gal-Or; Srinivas R Sadda; Lawrence A Yannuzzi; K Bailey Freund Journal: Clin Exp Ophthalmol Date: 2017-12-26 Impact factor: 4.207
Authors: Elon H C van Dijk; Jeppe K Holtz; Marc J Sirks; Janni M E Larsson; Roselie M H Diederen; Reinier O Schlingemann; Camiel J F Boon; Yousif Subhi Journal: J Clin Med Date: 2022-08-16 Impact factor: 4.964